Stoke Therapeutics Comes Out of Seed Mode With $40M and Ex-Sarepta CEO at Its Helm Post author:Sam Post published:January 3, 2018 Post category:BioPharma The Series A round was entirely funded by founding investor Apple Tree Partners. Source: BioSpace You Might Also Like Sartorius Stedim Biotech Supports Mainstream Adoption Of Quality By Design July 13, 2017 Is Medtronic's Artificial Pancreas The Next Big Thing In Diabetes? April 13, 2017 Aceto Subsidiary, Rising Pharma, Announces Product Launches July 20, 2017
